Explore the NIHProtocol Details
The Treatment of Menstrually-Related Mood Disorders with Continuous Gonadal Steroid Replacement
This study is currently recruiting participants.
Summary | Eligibility | Citations | Contacts
Summary
Number |
00-M-0103 |
Sponsoring Institute |
National Institute of Mental Health (NIMH) |
Recruitment Detail |
Type: Participants currently recruited/enrolled |
Referral Letter Required |
No |
Population Exclusion(s) |
Male; |
Special Instructions |
Call referral contact for additional eligibility criteria. |
Keywords |
Depression; |
Recruitment Keyword(s) |
Menstrually Related Mood Disorders |
Condition(s) |
Premenstrual Syndrome; |
Investigational Drug(s) |
None |
Investigational Device(s) |
None |
Intervention(s) |
None |
Supporting Site |
|
Studies indicate that women with PMS experience improvement in symptoms following treatment with leuprolide acetate, when estrogen and progesterone levels are low. Women with PMS, but not women without the disorder, experience a return of symptoms within approximately a week after re-exposure to either estrogen or progesterone. The cause of this hormone-induced depression remains unclear. It is not known whether this depressed mood is due simply to the change in the levels of estrogen and progesterone and whether it would remit following continued exposure to stable levels of estrogen and progesterone. This study will determine whether the maintenance of stable hormone levels will prevent mood disturbances in women with PMS.
Participants in this study will receive leuprolide acetate injections once a month for up to 6 months. After 2 months, women whose symptoms have improved will receive a skin patch containing either estrogen or placebo (an inactive substance) and will be asked to take daily suppositories containing either progesterone or placebo. Women whose symptoms of PMS do not respond to leuprolide treatment after 2 months will end the study and be offered other treatment. Participants will be seen by a nurse in the clinic every two weeks and will fill out ratings and have blood drawn to measure hormone levels.
Eligibility
INCLUSION CRITERIA:
The subjects of this study will be women who meet the criteria for MRMD as described in Protocol # 81-M-0126, The Phenomenology and Biophysiology of Menstrually-related Mood and Behavioral Disorders. In brief, these criteria include the following:
1) History within the last two years of at least six months with menstrually-related mood or behavioral disturbances of at least moderate severity--i.e., disturbances that are distinct in appearance and associated with a notable degree of subjective distress and interference with life activities;
2) Symptoms with a sudden offset and absence of significant symptomatology during the follicular phase;
3) Age 18-50;
4) Regular menstrual cycles (21-35 days in length), not pregnant, and in good medical health;
5) Not pregnant;
6) In good medical health;
5) Medication free.
All patients participating in this protocol will have already participated in Protocol No. 81-M-0126 and will have a prospectively confirmed and predictable relationship between their mood disorder and the premenstrual phase of the menstrual cycle; i.e., a 30% change in severity of symptom self rating scales, relative to the range of the scale employed, during the seven days premenstrually compared with the seven days post-menstrually in two out of three months of study. This method formed the basis of the NIMH PMS Workgroup diagnostic guidelines and produces results that are highly convergent with the effect size method for diagnosing PMS.
All subjects will be required to use non-hormonal forms of birth control (e.g. barrier methods with the exception of IUD's) to avoid pregnancy during this study.
EXLUSION CRITERIA:
The following conditions, also, will constitute contraindications to treatment with hormonal therapy and will preclude a patient's participating in this protocol:
1) Current Axis I psychiatric diagnosis
2) History of endometriosis;
3) Diagnosis of ill-defined, obscure pelvic lesions, particularly undiagnosed ovarian enlargement;
4) Hepatic disease as manifested by abnormal liver function tests;
5) History of mammary carcinoma;
6) History of pulmonary embolism or phlebothrombosis;
7) Undiagnosed vaginal bleeding;
8) Porphyries;
9) Diabetes mellitus;
10) History of malignant melanoma;
11) Cholecystitis or pancreatitis;
12) Cardiovascular or renal disease;
13) Pregnancy;
14) Significant clinical or laboratory abnormalities
Citations:
Contacts:
Principal Investigator |
Referral Contact |
For more information http://clinicalstudies.info.nih.gov. |
| Peter J. Schmidt, M.D. National Institute of Mental Health (NIMH) National Institutes of Health Building 10 Room 3C115 10 Center Drive Bethesda, Maryland 20892 (301) 435-4594 vsm@mail.nih.gov |
Peter J. Schmidt, M.D. National Institute of Mental Health (NIMH) National Institutes of Health Building 10 Room 3C115 10 Center Drive Bethesda, Maryland 20892 (301) 435-4594 vsm@mail.nih.gov |
Patient Recruitment and Public Liaison Office Building 61 10 Cloister Court Bethesda, Maryland 20892-4754 Toll Free: 1-800-411-1222 TTY: 301-594-9774 (local),1-866-411-1010 (toll free) Fax: 301-480-9793 prpl@mail.cc.nih.gov |
Clinical Trials Number:
NCT00005011
QUESTIONS?
Contact the Patient Recruitment and Public Liaison Office for:
- Details on how to participate in a study
- Details on how to refer a patient to a study
NIH Clinical Studies Information Request
Contact the Office of Communications for:
- General information about the NIH Clinical Center
Contact the Department Clinical Research Informatics, (DCRI) for:
- Technical questions about Adobe Acrobat and the PDF format
- Technical questions about this web server
